Kazia Therapeutics Limited ADR [NASDAQ: KZIA] price plunged by -20.61 percent to reach at -$0.08. The company report on February 21, 2024 at 7:30 AM that Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint.
Paxalisib plus Radiotherapy Data Shows Promise for Treating Patients with PI3K Pathway Mutation Brain Metastases.
Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on positive safety and promising clinical response findings observed to date of an important two-part Phase I trial. This investigator-initiated trial evaluated the use of paxalisib (an oral PI3K/mTOR dual inhibitor) with radiation therapy for the treatment of patients with PI3K pathway mutation brain metastases from solid tumors.
The one-year KZIA stock forecast points to a potential upside of 84.0. The average equity rating for KZIA stock is currently 1.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Kazia Therapeutics Limited ADR [KZIA]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for KZIA shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on KZIA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Maxim Group have made an estimate for Kazia Therapeutics Limited ADR shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 14, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on January 05, 2021, representing the official price target for Kazia Therapeutics Limited ADR stock.
The Average True Range (ATR) for Kazia Therapeutics Limited ADR is set at 0.06 The Price to Book ratio for the last quarter was 0.90, with the Price to Cash per share for the same quarter was set at 0.15.
KZIA Stock Performance Analysis:
Kazia Therapeutics Limited ADR [KZIA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 13.59. With this latest performance, KZIA shares dropped by -9.97% in over the last four-week period, additionally sinking by -65.97% over the last 6 months – not to mention a drop of -64.47% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KZIA stock in for the last two-week period is set at 47.73, with the RSI for the last a single of trading hit 49.85, and the three-weeks RSI is set at 45.25 for Kazia Therapeutics Limited ADR [KZIA]. The present Moving Average for the last 50 days of trading for this stock 0.3567, while it was recorded at 0.3329 for the last single week of trading, and 0.8040 for the last 200 days.
Insight into Kazia Therapeutics Limited ADR Fundamentals:
Kazia Therapeutics Limited ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.42 and a Current Ratio set at 1.42.
Kazia Therapeutics Limited ADR [KZIA] Institutonal Ownership Details
The top three institutional holders of KZIA stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in KZIA stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in KZIA stock with ownership which is approximately 5.8325%.
